Streetbeat News

Stock Prices

SINT

SiNtx Technologies shares rose after receiving a Notice of Allowance from the USPTO for a patent on surface functionalization of zirconia-toughed alumina with silicon nitride ceramic.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:13 pm

INTC

NVDA

Peter Schiff warns investors about the risks of irrational exuberance in tech stocks and cryptocurrencies, using Intel's decline as a cautionary tale. Intel has struggled due to product missteps and lack of vision, contrasting with Nvidia's success in AI. Intel's stock has significantly underperformed, and the company is considering cost-cutting measures.

Portfolio Pulse from Shanthi Rexaline

September 09, 2024 | 12:11 pm

BTCUSD

ETHUSD

JPMorgan's report highlights the need for new catalysts in the cryptocurrency market to boost retail engagement and reverse the recent downtrend. Despite a decline in market value, trading volumes for Bitcoin and Ethereum increased. However, ETFs tied to these cryptocurrencies underperformed, with Bitcoin ETFs experiencing net outflows.

Portfolio Pulse from Murtuza Merchant

September 09, 2024 | 12:11 pm

MEOH

MRK

Several major stocks, including Methanex, Merck, and others, are experiencing declines in Monday's pre-market session. Methanex's shares fell 6.3% after announcing a $2.05 billion acquisition of OCI Global's methanol business. Merck's shares dropped 4.8% following clinical trial results.

Portfolio Pulse from Avi Kapoor

September 09, 2024 | 12:11 pm

ORCL

Oracle Corporation is set to release its Q1 FY2025 earnings on September 9, with expectations of $1.33 EPS and $13.24 billion in revenue. Recent analyst ratings show mixed sentiments, with price targets ranging from $125 to $171.

Portfolio Pulse from Avi Kapoor

September 09, 2024 | 12:10 pm

PLTR

SMMT

TERN

Palantir Technologies (PLTR) shares rose 8% due to its addition to the S&P 500 index. Terns Pharmaceuticals (TERN) saw a 42% increase after announcing positive Phase 1 trial results for TERN-601. Summit Therapeutics (SMMT) shares surged 62% following successful trial results for Ivonescimab in treating advanced NSCLC.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:09 pm

CVX

DRIP

FANG

GUSH

MTDR

PR

XOM

Chevron and Exxon Mobil saw slight pre-market gains after last week's losses due to economic concerns. Direxion's leveraged oil ETFs, GUSH and DRIP, offer opportunities for bullish and bearish investors, respectively. GUSH is below key moving averages, while DRIP has gained due to falling oil prices.

Portfolio Pulse from Joshenomoto@benzinga.com

September 09, 2024 | 12:08 pm

ACTU

Actuate Therapeutics announced that its drug Elraglusib showed promising results in treating relapsed/refractory Ewing and Ewing-related sarcomas. In the first 8 patients, the drug achieved a 62% disease control rate and two ongoing durable complete responses.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:07 pm

CTMX

CytomX Therapeutics has dosed the first patient in a Phase 1 study of CX-801, targeting solid tumors. This marks a significant milestone in their clinical development program.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:06 pm

EVAX

Evaxion Biotech announced interim results from its Phase 2 trial of EVX-01, showing a 69% overall response rate with 15 out of 16 patients experiencing tumor reduction.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:05 pm